GLOBALKRATOM.ORG · Evidence-based policy resources
Global Kratom Policy Review icon
Global Kratom Policy Review
Research · Analysis · Policy

FDA Authority & Kratom:
Myth vs Fact

What the FDA can – and cannot – do under current federal law.

Myth vs Fact
❌ Myth
“FDA would ban it if it were dangerous.”

FDA cannot instantly ban a product based on safety concerns alone.

“FDA approval is required before supplements are sold.”

Most supplements do not require premarket approval.

“Sold in stores = FDA approved it as safe.”

Retail availability does not equal FDA safety determination.

“FDA has no concerns about kratom.”

FDA has repeatedly warned about liver toxicity, seizures, addiction, and deaths.

“FDA can remove all kratom products immediately.”

Enforcement is case‑by‑case, slow, and resource‑intensive.

“Import alerts mean a total ban.”

Import alerts stop incoming shipments but don’t affect domestic stock.

✓ Fact
No instant ban authority.

FDA must prove adulteration or misbranding; DSHEA limits its power.

No pre‑market approval.

Manufacturers are responsible for safety, not FDA.

Safety is not pre‑judged.

FDA acts after products are on the market — often years later.

Strong documented concerns.

Import alerts, warning letters, recalls, and public advisories since 2014.

Case‑by‑case enforcement.

Hundreds of vendors, complex litigation, resource limits.

Import alert ≠ prohibition.

Existing domestic supply can remain unless further action is taken.

Important clarification regarding the FDA‑funded Single Ascending Dose (SAD) study on kratom:

FDA provided a grant for the study – but FDA did not conduct it. The study was performed by an independent contract research organization.

FDA has NOT determined that kratom is safe based on this study. The study does not constitute FDA approval, safety clearance, or a change in the agency’s position that kratom is not lawfully marketed and poses serious health risks.

What FDA Can — and Cannot — Easily Do

✓ Can Do

  • Issue warning letters
  • Issue import alerts (e.g., 54‑15)
  • Pursue recalls (voluntary & mandatory)
  • Seize adulterated products
  • Challenge false disease claims
  • Issue public health advisories
  • Refer substances to DEA for scheduling

✗ Cannot Easily Do

  • Instantly remove every product nationwide
  • Require premarket approval for all supplements
  • Unilaterally schedule substances
  • Criminalize possession alone
  • Inspect every retailer
  • Rapidly litigate hundreds of violative products

Why DSHEA (1994) Matters

Dietary supplements generally enter the market without pre‑approval. FDA acts after products are already sold. Proving adulteration is complex and slow. Kratom has never been lawfully marketed as a dietary ingredient, but enforcement gaps allow continued sales.

Federal Actions on Kratom
2014
Import Alert 54‑15 – detention of kratom supplements at ports.
2016
US Marshals seize 90,000 bottles of kratom products (>$400,000).
2017
FDA public health advisory warning consumers not to use kratom.
2018
First mandatory recall order (Salmonella contamination).
2024
FDA warns against OPMS Black Liquid Kratom after reported death.
2025
Warning letter to Hydroxie (7‑OH products) as unapproved new drugs.

Why This Matters for Policymakers

Federal regulatory authority is structurally limited and procedurally complex. Absence of a ban does not equal safety. Understanding these limits helps explain why state legislatures, boards of pharmacy, and other agencies continue to debate kratom regulation.